By Dennis Thompson
HealthDay Reporter

WEDNESDAY, April 29, 2020 (HealthDay News) — Two new reports have produced conflicting results on the potential effectiveness of remdesivir, an experimental antiviral drug considered to be one of the leading hopes in the fight against COVID-19.

Disappointing results emerged from the first gold-standard clinical trial for remdesivir, which found that the drug did not help patients in China with severe COVID-19. Those findings were published April 29 in The Lancet medical journal.

On the same day, drugmaker Gilead Sciences announced positive early findings from a U.S.-designed clinical trial being